Stay updated with breaking news from Nasdaq Carm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) had its price target boosted by equities research analysts at HC Wainwright from $10.00 to $11.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 74.33% from […]
Carisma Therapeutics (NASDAQ:CARM – Get Free Report) and Innovus Pharmaceuticals (OTCMKTS:INNVD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Profitability This table compares Carisma Therapeutics and […]
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 2,450,000 shares, an increase of 7.9% from the June 30th total of 2,270,000 shares. Approximately 13.3% of the shares of the company are […]
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Free Report) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 2,450,000 shares, an increase of 7.9% from the June 30th total of 2,270,000 shares. Based on an average trading volume of 314,700 shares, the days-to-cover ratio is currently 7.8 […]
Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Rating) was the target of a significant drop in short interest during the month of May. As of May 31st, there was short interest totalling 521,900 shares, a drop of 18.1% from the May 15th total of 636,900 shares. Based on an average daily trading volume, of 179,900 shares, […]